ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer
ImmunityBio shares jumped 24% to $6.82 midday Tuesday after the FDA gave guidance that could allow resubmission of its ANKTIVA bladder cancer drug without requiring a new clinical trial. The stock traded as high as $7.97 on heavy volume. The FDA requested more data but did not grant approval. ImmunityBio plans to submit additional information within 30 days.